Affimed Presents New Preclinical Data on Bi- and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Affimed Presents New Preclinical Data on Bi- and Trispecific Immune Cell Engagers at ASH

HEIDELBERG, Germany, Dec. 06, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD ), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the presentation of preclinical data from three studies at the 58 th American Society of Hematology (ASH) Annual Meeting and Exposition 2016 in San Diego, California.

“We continue to generate data that further elucidate the mechanism of action of our drugs as well as the activation of NK-cells by our CD16A-engaging bispecific antibodies. Studies with our lead drug AFM13 showed that the combination with IL-2 or IL-15 had a synergistic effect on AFM13-mediated expansion, which is induced by an upregulation of the respective interleukin receptors on NK-cells,” said Dr. Adi Hoess, CEO of Affimed. “In addition, we are working to overcome the hurdle represented by the limited number of tumor-specific targets for T- or NK-cell engagement by developing trispecific tetravalent antibodies, which show increased tumor cell selectivity.

AFM13

On Saturday, December 3, the Company and its collaboration partner, the German Cancer Research Center (DKFZ), Heidelberg, presented a poster (Abstract #1764) sharing additional insights into the mechanism of action of lead product candidate AFM13, a CD30/CD16A-specific NK-cell engager. Expanding on previous studies demonstrating synergistic efficacy of AFM13 when combined with checkpoint modulation (e.g. anti-PD-1), the poster identifies other potential future candidates for AFM13 combination therapies, as well as biomarkers that may be predictive of NK-cell responses to AFM13 treatment.

In vitro, NK-cell cytotoxicity towards CD30+ tumor cells and IFN-γ production were substantially increased in the presence of AFM13, and AFM13 was significantly more potent than a native anti-CD30 IgG1 antibody. A detailed analysis showed that interaction of NK-cells with AFM13-coated tumor cells up-regulated the expression of NK-cell surface receptors such as CD25, CD69 and CD137/4-1BB, as well as additional markers that may serve as NK-cell checkpoints. Importantly, AFM13-mediated CD16A engagement enhanced the potential of NK-cells for proliferation and expansion when subsequently incubated with the cytokines IL-15 or IL-2. This effect was observed even in target cells resistant to naïve NK-cells and to NK-cells activated only with IL-2/IL-15.

In summary, the data presented at ASH demonstrates that AFM13 specifically enhances the cytotoxic, proliferative and cytokine-producing potential of NK-cells. In addition, the results indicate that the distinctive modulation of NK-cell receptors can be utilized to monitor NK-cell responses during AFM13 therapy and to select candidates for therapeutic combination strategies.

AFM11

In a poster presented on Monday, December 5, Affimed along with its collaboration partners from University Hospital Wuerzburg, determined the effects of treatment history on T-cell engagement (Abstract #4130). Specifically, the researchers analyzed the activity of the CD19/CD3-specific TandAb AFM11 on T-cells derived from NHL patients after different chemotherapeutic regimens (R-Bendamustine, R-CHOP and HD-BEAM), compared to T-cells from healthy donors. Even though patient T-cells were significantly reduced in number after chemotherapy and displayed functional defects, AFM11 was able to activate them for potent target cell lysis with comparable efficacy to T-cells from healthy donors. Lower efficacy was only observed at limiting effector cell counts.

The study also reported that the type of prior chemotherapeutic regimen had an effect on AFM11-mediated T-cell engagement. While T-cells from patients treated with R-CHOP displayed responsiveness similar to T-cells from healthy donors, lower cytotoxic activity was measured for T-cells from R-Bendamustine and HD-BEAM pretreated patients.

In summary, T-cell-engaging immunotherapies such as bispecific T-cell-recruiting antibodies or chimeric antigen receptor T-cells (CAR-T) have emerged as highly active therapeutics in hematological malignancies and these results highlight the importance of taking the specifics of chemotherapeutic pretreatment into account in the planning of immuno-oncology trials.

Trispecific Antibodies

In another poster on Monday, December 5, Affimed presented details on its trispecific antibody format being investigated in a multiple myeloma (MM) model system (Abstract #4513). TandAbs are tetravalent antibodies and thereby show bivalent binding to both cancer and immune cells. The Company has engineered trispecific tetravalent antibodies that redirect NK-cells to tumor cells co-expressing two surface antigens (‘dual-targeting’), thereby leading to increased tumor cell selectivity. Due to its largely tumor cell-specific expression profile, B-cell maturation antigen (BCMA/CD269) has emerged as a promising target antigen for antibody-based therapies of MM. CD200 was selected as the second MM-expressed surface antigen found in the majority of patients. In vitro , the trispecific antibodies selectively engaged NK-cells through bivalent binding to CD16A and monovalent binding to both BCMA and to CD200. Binding to BCMA+/CD200+ cells and the resulting increase in avidity led to preferential lysis of antigen double-positive cells compared with antigen single-positive cells. These data suggest that dual-targeting may increase the therapeutic window compared to approaches targeting only one antigen.

About Affimed N.V.

Affimed (Nasdaq: AFMD ) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com .

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates our intellectual property position, our collaboration activities, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in Affimed’s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

IR Contact:

Caroline Stewart, Head IR Phone: +1 347394 6793 E-Mail: IR@affimed.com or c.stewart@affimed.com

Media Contact:

Anca Alexandru, Head of Communications, EU IR Phone: +49 6221 64793341 E-Mail: a.alexandru@affimed.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 27

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 121

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Condo Downsizing Demands More Than a Price Check Today

Updated Category News Views 58

A smaller front door can hide a surprisingly large stack of obligations. That is the useful point in the HelloNation guidance featuring Chevy Chase real estate expert Lise Howe: downsizing into a condo is not merely a square-footage trade. It is a decision about recurring costs, building stewardship, daily friction, and whether the place still works when life gets less...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 128

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Dubai's 2028 Fire Congress Puts Global Safety Tech on Stage

Updated Category News Views 38

Fire engines, wildfires, dense towers, and AI are all colliding in Dubai's next big public-safety moment. The World Fire Congress has handed its 2028 host role to Dubai, making this the first time the biennial gathering of global fire and emergency-service leaders will land in the Middle East. That is not a quarterly earnings event, and nobody ought to pretend it is....

Continue Reading
PostalAnnex Adds Roseville Store as Owners Reach Three

Updated Category News Views 31

A third storefront from the same operators says more than a ribbon-cutting ever will. Aarondeep Hira and Manraj Sangha have opened a PostalAnnex in Roseville, California, their third Sacramento-area location after earlier operations in Sacramento and Antelope. For a franchise system, repeat ownership is the part worth noticing. It is not a guarantee of booming sales, and...

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 279

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 186

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
Shenzhen's Vertical Factories Put Robotics on Fast Track

Updated Category News Views 100

A truck climbing to a ninth-floor factory is the sort of detail that cuts through the usual innovation fog. Shenzhen's Honghualing industrial base in Nanshan is built around that odd-looking reality: keep engineers, component makers, automated lines and test customers stacked close together, then squeeze time out of the process. For anybody watching robotics, LiDAR and...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 75

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Update: Heroes Made Joins AWS Marketplace for Schools

Updated Category News Views 120

Heroes Made's Significant Partnership with GG4L Heroes Made, a top provider of Social and Emotional Learning (SEL) solutions for students, proudly announces its incorporation into the AWS Marketplace, specifically as part of Global Grid for Learning's (GG4L) SchoolDay Collection. This progressive collaboration aims to streamline how schools access and utilize effective...

Continue Reading
Palisade Bio Secures $138 Million to Advance Clinical Programs

Updated Category News Views 173

Palisade Bio Secures Substantial Funding to Propel Clinical Trials Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company dedicated to innovating therapies for autoimmune and inflammatory diseases, recently announced the successful closing of an impressive public offering, which raised gross proceeds of approximately $138 million. This significant...

Continue Reading
Enlight's Snowflake A Project Boosts Renewable Energy Capacity

Updated Category News Views 46

Enlight Renewable Energy's New Power Purchase Agreement Enlight Renewable Energy, a noteworthy player in the renewable energy sector, recently announced exciting developments regarding its U.S. subsidiary, Clenera. They have successfully signed a power purchase agreement (PPA) with Arizona Public Service (APS) for the Snowflake A Project, which aims to bolster clean...

Continue Reading
BigBear.ai Faces Investigation Amidst Financial Restatement Concerns

Updated Category News Views 446

BigBear.ai Holdings Under Investigation BigBear.ai Holdings, Inc. (NYSE: BBAI) is currently the focus of an investigation initiated by legal representatives. This comes as a response to growing concerns among investors regarding potential inaccuracies within the company’s financial reporting. Recent disclosures made by BigBear indicate that their financial statements...

Continue Reading
Morgan Stanley's CEO Ted Pick Ascends to Chairman Role

Updated Category News Views 90

Ted Pick Takes the Helm as Chairman of Morgan Stanley In an exciting leadership development, Morgan Stanley (NYSE: MS) has named its current CEO, Edward (Ted) Pick, as the new Chairman of the Board, effective January 1, 2025. This transition comes as the firm prepares for the retirement of the current Chairman, James Gorman, who will take on the honorary title of Chairman...

Continue Reading